兒童失神性癲癇治療市場：依藥物、疾病類型和地區分類

Childhood Absence Epilepsy Treatment Market, By Drug, By Disease Type, By Geography

出版日期: 2026年06月02日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，兒童失神性癲癇治療市場規模將在 2026 年達到 3 億美元，預計到 2033 年將達到 5.2 億美元。預計 2026 年至 2033 年的複合年成長率將達到 8.2%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	3億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	8.20%	2033年市場規模預測：	5.2億美元

兒童失神性癲癇的診斷重點在於識別症狀並根據這些症狀對癲癇類型進行分類。兒童失神性癲癇的診斷方法和技術包括腦電圖（EEG）/視訊遙測、磁振造影（MRI）和血液檢查。在腦電圖/視訊遙測中，患者需要過度換氣3-5分鐘以誘發失神發作，並將大腦的電訊號記錄在電腦上。腦電圖結果顯示頻率為3 Hz（每秒週期數）的棘慢波放電，並證實其性質為整體（大腦兩側出現相似的模式）。 MRI可以辨識癲癇的結構性病因（一些由腦損傷引起的癲癇患者是透過MRI發現的）。血液檢查也可能是必要的，以診斷可能導致癲癇的潛在疾病。

市場動態

市場上的主要參與者正致力於研發治療兒童失神性癲癇的新藥。疾病盛行率的上升、藥物可及性的提高以及正在研發用於治療兒童失神性癲癇的藥物（如Insys Therapeutics和Cavion, Inc.）等因素預計將推動全球兒童失神性癲癇治療市場的成長。美國及全球學名藥生產商推出的新產品預計也將促進市場成長。例如，瑞迪博士實驗室（Dr. Reddy's Laboratories）於2016年在美國推出了拉莫三嗪的非專利口溶錠。此外，包括Insys Therapeutics（大麻二酚）和Cavion, Inc.（CX-8998）在內的多家生產商的藥物正處於II期臨床試驗階段，預計這些療法將在預測期內上市。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、區域前景以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球兒童失神性癲癇治療市場主要參與者的概況：公司概況、財務績效、產品系列、企業發展區域、分銷策略以及關鍵發展和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、技術升級、市場擴張和行銷策略做出明智的決策。
這份「全球兒童失神性癲癇治療市場」報告的目標受群眾外包括產業內的各類相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用分析兒童失神性癲癇治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Cavion, Inc.
- Pfizer, Inc.
- GlaxoSmithKline Plc
- Insys Therapeutics, Inc.
- AbbVie, Inc.
- Teva Pharmaceutical Industries Ltd.
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2329

Childhood Absence Epilepsy Treatment Market is estimated to be valued at USD 300 Mn in 2026 and is expected to reach USD 520 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 300 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	8.20%	2033 Value Projection:	USD 520 Mn

Childhood absence epilepsy diagnosis revolves around identifying symptoms and categorizing the epilepsy type based on those symptoms. Diagnostic methods and techniques for childhood absence epilepsy include electroencephalogram (EEG)/video telemetry, magnetic resonance imaging (MRI scans), and blood tests. In electroencephalogram (EEG)/video telemetry, electrical signals from brain are recorded in a computer by asking the patient to hyperventilate for 3 to 5 minutes, which triggers an absence seizure. The EEG then shows spikes and wave discharges at 3 Hz (cycles per second) that are generalized in nature (similar on both sides of the brain). Structural causes behind epilepsy can be understood with the help of MRI scans (as some patients suffering from epilepsy due to brain damage can be found by a MRI scan). Blood tests may be required to diagnose any medical conditions, which may be the reason behind epilepsy.

Market Dynamics

Key players in the market are focused on the development of new drugs for the treatment of childhood absence epilepsy. Factors such as increasing prevalence of the disease, increasing accessibility of medications, and presence of drugs in pipeline for childhood absence epilepsy treatment (Insys therapeutics and Cavion, Inc.) are expected to boost the global childhood absence epilepsy treatment market growth. Product launches by generic manufacturers in the U.S. as well as globally is expected to support growth of the market. For instance, Dr. Reddy's Laboratories launched generic lamotrigine orally disintegrating tablets in the U.S. in 2016. Moreover, a number of manufacturers such as Insys Therapeutics (Cannabidiol) and Cavion, Inc. (CX-8998) have drugs in phase II stage in clinical trials and these therapies are expected to be launched over the forecast period.

Key features of the study

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global childhood absence epilepsy treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies
Key companies covered as a part of this study include Cavion, Inc., Pfizer, Inc., GlaxoSmithKline Plc, Insys Therapeutics, Inc., AbbVie, Inc., and Teva Pharmaceutical Industries Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, by technology up-gradation, market expansion, and marketing tactics
The global childhood absence epilepsy treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the childhood absence epilepsy treatment market

Market Segmentation

By Drug (Revenue, USD Mn, 2021-2033)
Ethosuximide
Valproate
Lamotrigine
Phase 2 Drugs
- Cannabidiol Oral Solution
- CX-8998
By Disease Type (Revenue, USD Mn, 2021-2033)
Typical Absence Seizures
Atypical Absence Seizures
By Region (Revenue, USD Mn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Cavion, Inc.
Pfizer, Inc.
GlaxoSmithKline Plc
Insys Therapeutics, Inc.
AbbVie, Inc.
Teva Pharmaceutical Industries Ltd.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug
- Market Snapshot, By Disease Type
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Childhood Absence Epilepsy Treatment Market, By Drug, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Ethosuximide
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Valproate
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Lamotrigine
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Phase 2 Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
- Segment Trends
  - Cannabidiol Oral Solution
  - CX-8998

5. Global Childhood Absence Epilepsy Treatment Market, By Disease Type, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Typical Absence Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Atypical Absence Seizures
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Global Childhood Absence Epilepsy Treatment Market, By Region, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Cavion, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- GlaxoSmithKline Plc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Insys Therapeutics, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- AbbVie, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views